Sunesis Pharmaceuticals (FRA:RYIS) Total Liabilities : €2.72 Mil (As of Dec. 2020)

View and export this data going back to 2007. Start your Free Trial

What is Sunesis Pharmaceuticals Total Liabilities?

Sunesis Pharmaceuticals's Total Liabilities for the quarter that ended in Dec. 2020 was €2.72 Mil.

Sunesis Pharmaceuticals's quarterly Total Liabilities declined from Jun. 2020 (€8.35 Mil) to Sep. 2020 (€3.03 Mil) and declined from Sep. 2020 (€3.03 Mil) to Dec. 2020 (€2.72 Mil).

Sunesis Pharmaceuticals's annual Total Liabilities declined from Dec. 2018 (€9.96 Mil) to Dec. 2019 (€8.73 Mil) and declined from Dec. 2019 (€8.73 Mil) to Dec. 2020 (€2.72 Mil).

Sunesis Pharmaceuticals Total Liabilities Historical Data

The historical data trend for Sunesis Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sunesis Pharmaceuticals Total Liabilities Chart

Sunesis Pharmaceuticals Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Total Liabilities

Get a 7-Day Free Trial

21.06

10.81

9.96

8.73

2.72

Sunesis Pharmaceuticals Quarterly Data
	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20
Total Liabilities	Get a 7-Day Free Trial															8.73	8.51	8.35	3.03	2.72

Sunesis Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Sunesis Pharmaceuticals's Total Liabilities for the fiscal year that ended in Dec. 2020 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	2.721	+	(0	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	2.72

Total Liabilities	=	Total Assets (A: Dec. 2020 )	-	Total Equity (A: Dec. 2020 )
	=	19.109	-	16.388
	=	2.72

Sunesis Pharmaceuticals's Total Liabilities for the quarter that ended in Dec. 2020 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	2.721	+	(0	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	2.72

Total Liabilities	=	Total Assets (Q: Dec. 2020 )	-	Total Equity (Q: Dec. 2020 )
	=	19.109	-	16.388
	=	2.72

Sunesis Pharmaceuticals Total Liabilities Related Terms

Thank you for viewing the detailed overview of Sunesis Pharmaceuticals's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Sunesis Pharmaceuticals (FRA:RYIS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sunesis Pharmaceuticals Inc (FRA:RYIS) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

395 Oyster Point Boulevard, Suite 400, South San Francisco, CA, USA, 94080

Website

http://www.sunesis.com

Sunesis Pharmaceuticals Inc is a US-based biopharmaceutical company. It focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The product portfolio of the company includes Vosaroxin which is an anticancer quinolone derivative for the treatment of acute myeloid leukemia (AML). The company's other kinase inhibitor pipeline includes TAK-580, SNS-062, and SNS-229. Further, the firm's activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The firm derives substantially the majority of revenue from license and collaboration agreements.

Sunesis Pharmaceuticals (FRA:RYIS) Headlines

No Headlines